Posts by: Joana Carvalho, PhD

Joana Carvalho, PhD

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

July 2, 2020July 2, 2020

FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma — a type of bladder cancer — whose ... Read more

July 1, 2020July 1, 2020

FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for people with inoperable or metastatic colorectal cancer with specific genetic features that denote a ... Read more

June 29, 2020June 29, 2020

EMA Asked to Conditionally Approve Gliovac, Cancer Vaccine, for Recurrent Glioblastoma

News

ERC Belgium has asked the European Medicines Agency (EMA) to give conditional approval to its investigational anti-cancer vaccine Gliovac (ERC1671) for the treatment of recurrent glioblastoma, an aggressive form of brain ... Read more

June 24, 2020June 24, 2020

Keytruda Approved in China as Second-line Therapy for Advanced Esophageal Cancers

News

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a second-line therapy for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors ... Read more

June 12, 2020June 12, 2020

FDA Approves Opdivo for Advanced Esophageal Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) previously treated ... Read more

June 3, 2020June 3, 2020

FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of newly diagnosed patients with advanced hepatocellular carcinoma (HCC), the ... Read more

June 1, 2020June 1, 2020

Surface, Merck Partner on SRF617-Keytruda Combo Targeting Solid Tumors

News

Surface Oncology has entered a collaboration with Merck to investigate a combination of SRF617 and Keytruda (pembrolizumab) in patients with solid tumors, with a particular focus on individuals with ... Read more

December 17, 2019December 20, 2019

PharmaMar Asks FDA for Accelerated Approval of Lurbinectedin to Treat Relapsed SCLC

News

PharmaMar is asking the U.S. Food and Drug Administration (FDA) to approve lurbinectedin (PM1183) to treat those with small cell lung cancer (SCLC) whose disease progressed following platinum-based chemotherapy. The ... Read more

December 11, 2019

Single-Blinded Trial Design Prevents Patients From Withdrawing Prematurely, Analysis Shows

News

BeyondSpring’s single-blinded trial design, in which patients are unaware of the treatment they receive, effectively prevented participants from prematurely withdrawing from the company’s DUBLIN-3 study due to dissatisfaction with ... Read more

December 5, 2019December 6, 2019

Tecentriq-chemo Combo OK’d as First-line Treatment for Certain Metastatic NSCLC Patients

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous ... Read more

Pin It on Pinterest